Literature DB >> 7983757

Amphotericin B derivative blocks human immunodeficiency virus type 1 entry after CD4 binding: effect on virus-cell fusion but not on cell-cell fusion.

O Pleskoff1, M Seman, M Alizon.   

Abstract

The antiviral effect of MS8209, an amphotericin B derivative, was studied in CD4+ cells transfected with a lacZ gene inducible upon human immunodeficiency virus type 1 (HIV-1) infection. MS8209 was shown to block virus entry after receptor binding and probably before virus-cell membrane fusion, but it had no effect on syncytium formation, although both processes are mediated by HIV-1 envelope proteins and CD4.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7983757      PMCID： PMC188612          DOI： 10.1128/JVI.69.1.570-574.1995

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  31 in total

1.  Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.

Authors:  M Kowalski; J Potz; L Basiripour; T Dorfman; W C Goh; E Terwilliger; A Dayton; C Rosen; W Haseltine; J Sodroski
Journal:  Science       Date:  1987-09-11       Impact factor: 47.728

2.  Anti-viral activity of amphotericin B methyl ester: inhibition of HTLV-III replication in cell culture.

Authors:  C P Schaffner; O J Plescia; D Pontani; D Sun; A Thornton; R C Pandey; P S Sarin
Journal:  Biochem Pharmacol       Date:  1986-11-15       Impact factor: 5.858

Review 3.  Human and simian immunodeficiency viruses: virus-receptor interactions.

Authors:  N Signoret; P Poignard; D Blanc; Q J Sattentau
Journal:  Trends Microbiol       Date:  1993-12       Impact factor: 17.079

Review 4.  How do the polyene macrolide antibiotics affect the cellular membrane properties?

Authors:  J Bolard
Journal:  Biochim Biophys Acta       Date:  1986-12-22

5.  Photoinactivation and kinetics of membrane fusion mediated by the human immunodeficiency virus type 1 envelope glycoprotein.

Authors:  D S Dimitrov; R Blumenthal
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

6.  Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding.

Authors:  H A Harrop; D R Coombe; C C Rider
Journal:  AIDS       Date:  1994-02       Impact factor: 4.177

7.  Fusion from without directed by human immunodeficiency virus particles.

Authors:  F Clavel; P Charneau
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

8.  Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro.

Authors:  M Baba; R Pauwels; J Balzarini; J Arnout; J Desmyter; E De Clercq
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

9.  Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin.

Authors:  D Meruelo; G Lavie; D Lavie
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

10.  Impairment of T cell receptor-dependent stimulation in CD4+ lymphocytes after contact with membrane-bound HIV-1 envelope glycoprotein.

Authors:  O Schwartz; M Alizon; J M Heard; O Danos
Journal:  Virology       Date:  1994-01       Impact factor: 3.616
View more
  17 in total

1.  Effects of MS-8209, an amphotericin B derivative, on tumor necrosis factor alpha synthesis and human immunodeficiency virus replication in macrophages.

Authors:  P Clayette; M Martin; V Beringue; N Dereuddre-Bosquet; K T Adjou; M Seman; D Dormont
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41.

Authors:  B Labrosse; O Pleskoff; N Sol; C Jones; Y Hénin; M Alizon
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  The cytomegalovirus-encoded chemokine receptor US28 can enhance cell-cell fusion mediated by different viral proteins.

Authors:  O Pleskoff; C Tréboute; M Alizon
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

4.  Postbinding events mediated by human immunodeficiency virus type 1 are sensitive to modifications in the D4-transmembrane linker region of CD4.

Authors:  S Moir; J Perreault; L Poulin
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

5.  Possible role of the V3 domain of gp120 in resistance to an amphotericin B derivative (MS8209) blocking human immunodeficiency virus entry.

Authors:  O Pleskoff; N Sol; H Marrakchi; M Serlin; M Seman; M Alizon
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

6.  The Amino Acid at Position 8 of the Proteolytic Cleavage Site of the Mumps Virus Fusion Protein Affects Viral Proteolysis and Fusogenicity.

Authors:  Sarah Hüttl; Markus Hoffmann; Torsten Steinmetzer; Christian Sauder; Nadine Krüger
Journal:  J Virol       Date:  2020-10-27       Impact factor: 5.103

7.  Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1.

Authors:  Xinzhen Yang; Svetla Kurteva; Xinping Ren; Sandra Lee; Joseph Sodroski
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

8.  Cleavage inhibition of the murine coronavirus spike protein by a furin-like enzyme affects cell-cell but not virus-cell fusion.

Authors:  Cornelis A M de Haan; Konrad Stadler; Gert-Jan Godeke; Berend Jan Bosch; Peter J M Rottier
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

9.  Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor.

Authors:  P F Lin; H Samanta; C M Bechtold; C A Deminie; A K Patick; M Alam; K Riccardi; R E Rose; R J White; R J Colonno
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

10.  The Role of Lipids in Retrovirus Replication.

Authors:  Abdul A Waheed; Eric O Freed
Journal:  Viruses       Date:  2010-05-01       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.